The serum expression levels of a 3 lncRNA panel, which includes CCAT2, were able to distinguish early-stage cervical cancer patients from normal controls, with an area under the curve of 0.894, 67.1% sensitivity, and 96.1% specificity [95]. The gene discussed is CCAT2; the disease is cervical carcinoma.